Pfizer (NYSE:PFE) Releases Earnings Results

Pfizer (NYSE:PFE) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09, Briefing.com reports. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 EPS.

Pfizer Stock Performance

PFE opened at $26.68 on Tuesday. The company has a 50 day simple moving average of $25.54 and a two-hundred day simple moving average of $25.05. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market cap of $151.67 billion, a P/E ratio of 15.51 and a beta of 0.47. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s payout ratio is currently 100.00%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat consensus ($0.66 EPS vs. ~ $0.56–$0.57 expected) and margins held up, showing underlying demand for legacy drugs like Eliquis offsetting COVID declines. Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: Pfizer reported Phase 2b results for its ultra‑long‑acting injectable GLP‑1 (PF’3944 / MET‑097i) showing around 12–12.3% weight loss with monthly dosing — a meaningful pipeline win that supports future growth beyond COVID-era sales. Pfizer’s Ultra‑Long‑Acting Injectable GLP‑1 RA Shows Robust and Continued Weight Loss
• Positive Sentiment: Pfizer is pursuing vaccine refresh opportunities (using Novavax’s Matrix‑M adjuvant) to bolster its vaccine pipeline and potential future vaccine revenue. Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story
• Neutral Sentiment: The company reaffirmed its modest 2026 outlook — reducing surprise risk but signaling limited upside in the near term. Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
• Neutral Sentiment: Analyst moves were mixed: Cantor raised its price target to $27 (reflecting pipeline optimism) while Goldman Sachs remains Neutral, citing rising margin pressure from upcoming patent losses. Cantor Fitzgerald Raises Pfizer PT to $27 Goldman Sachs Maintains Neutral on Pfizer
• Negative Sentiment: Management warned of near‑term profit declines and flagged a material impact from patent expirations (analysts cite roughly a $1.5B headwind), which pressures 2026 revenue and margins. Pfizer projects annual revenue decline amid $1.5B hit from patent cliffs
• Negative Sentiment: Despite the positives, the stock slipped as investors focused on margin pressure, policy/pricing headwinds and the need for cost cuts to offset declines — raising short‑term risk to the share price. Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.

Analyst Ratings Changes

A number of research firms have commented on PFE. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Citigroup assumed coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, HSBC reiterated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.06.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quest Investment Management LLC increased its position in shares of Pfizer by 1.3% during the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares during the last quarter. WealthCollab LLC boosted its stake in Pfizer by 12.5% in the second quarter. WealthCollab LLC now owns 3,985 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 442 shares in the last quarter. Abel Hall LLC grew its position in Pfizer by 1.7% during the third quarter. Abel Hall LLC now owns 26,342 shares of the biopharmaceutical company’s stock valued at $671,000 after acquiring an additional 442 shares during the last quarter. Vivaldi Capital Management LP raised its stake in shares of Pfizer by 3.4% during the second quarter. Vivaldi Capital Management LP now owns 14,438 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 472 shares in the last quarter. Finally, Guardian Investment Management lifted its holdings in shares of Pfizer by 4.1% in the 3rd quarter. Guardian Investment Management now owns 14,310 shares of the biopharmaceutical company’s stock worth $365,000 after acquiring an additional 558 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.